IRVINE, Calif.--(BUSINESS WIRE)-- Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation ...

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel ...

IRVINE, Calif.--(BUSINESS WIRE)-- Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation ...

Boston Scientific Corporation (NYSE:BSX) has agreed to acquire Axonics Inc (NASDAQ: AXNX) for $71 in cash per share, representing an enterprise value of approximately $3.4 billion and an equity value ...

Like Medtronic’s recently approved InterStim X, Axonics’ F15 sacral neuromodulation implant is designed to treat bladder and bowel dysfunction by stimulating the sacral nerve, but it outstrips its ...

The deal also includes potential milestone payments to the London-based Contura of $35 million, should Bulkamid top $50 million in rolling 12-month sales before the end of 2024. (Getty Images) () ...

Medtronic is upping the ante in a patent dispute with competitor Axonics Inc. that has already lasted more than four years. The dispute centers on Medtronic’s InterStim device, an implanted ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

An Axonics sacral neuromodulation system sends electrical signals to nerves in the spinal cord to help regulate the bladder and bowels Device maker Axonics Inc. says its newest system designed to ...

Axonics presents with robust fundamentals and unit economics around its sacral neuromodulation segment. The company confirmed FY22 numbers above consensus, guides to FY23E revenues above the Street as ...